AHN Cancer Center Launches RANDY’S Trial for Peritoneal Fibrosis - The Clinical Trial Vanguard
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Fibrosis, the dense scar tissue that can entangle peritoneal tumors and the healthy organs around them, is one reason cytoreduction surgery is denied to a portion of patients with appendiceal and other abdominal cancers. Allegheny Health Network Cancer Center’s newly launched RANDY’S Trial is built on a direct answer to that problem: test whether FDA-approved drugs already on the market can remodel that scar tissue and bring more patients into surgical eligibility. The trial did not emerge from a pharma pipeline or an NIH grant. A single community gala, the La Sera d’Oro event, raised $44,000 in 2025 to fund it.
The acronym stands for Repurposed And Naturally-Derived Drugs for the Treatment of Fibrosis in Peritoneal Carcinomatosis. Principal investigator Patrick Wagner, a surgical oncologist at AHN, is leading a multidisciplinary team that will evaluate existing medications for their ability to break down or remodel abdominal scar tissue. The mechanism matters because fibrosis does two things that complicate surgery: it obscures the boundary between healthy and diseased tissue, and it can trap cancer cells that are then left behind when a surgeon separates planes.
This article is an excerpt. To read the full content, visit the original source. The Clinical Trial Vanguard
Related articles
Three Ways a Pulmonary Fibrosis Lung Health Navigator Can Support You - American Lung Association
Spatial map of the lung reveals cellular mechanisms driving damage and fibrosis in severe COVID-19 - Medical Xpress
A lung affected by deadly forms of COVID-19 not only loses essential cells for breathing but also undergoes profound changes in its internal organization and the way its cells communicate with each other. A study involving the Sant Pau Research Institute (IR Sant Pau), published in Nature Communications, has created a spatial map of this transformation and identified some of the molecular mechanisms that accompany the progression of lung damage and fibrosis.
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!